{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:33Z","timestamp":1791388113230,"version":"4.3.3"},"reference-count":56,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,9,4]],"date-time":"2016-09-04T00:00:00Z","timestamp":1472947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>In an era of controversy in regard to \u2018hydroxyurea\u2010leukaemogenicity\u2019 and when interferon\u2010alfa2 (<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) is being revived in the treatment of Philadelphia\u2010negative myeloproliferative neoplasms (<jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content>s), we aim in this single\u2010centre observational study to describe the frequencies of second malignancies in a cohort of <jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content> patients treated with hydroxyurea (<jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content>) or <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> monotherapy or the combination of these agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Records of a <jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content> cohort of 196 patients were reviewed, and a retrospective analysis was performed on 90 patients treated with <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content>, 38 patients treated with <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> and 68 patients treated with both <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content>. Logistic regression was used to compare frequencies in second malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients treated with <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> had a significantly higher risk of developing all second malignancies compared with patients treated with <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> [<jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>:<jats:styled-content style=\"fixed-case\"> OR<\/jats:styled-content> of 4.01 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 1.12\u201314.27, <jats:italic>P<\/jats:italic>\u2010value: 0.023) and <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>:<jats:styled-content style=\"fixed-case\"> OR<\/jats:styled-content> 5.58 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 1.55\u201320.15, <jats:italic>P<\/jats:italic>\u2010value: 0.004)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We have found an increased risk of second malignancies in <jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content> patients treated with <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> compared with patients treated with <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12787","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T02:59:29Z","timestamp":1473044369000},"page":"75-84","source":"Crossref","is-referenced-by-count":34,"title":["Second malignancies in hydroxyurea and interferon\u2010treated Philadelphia\u2010negative myeloproliferative neoplasms"],"prefix":"10.1111","volume":"98","author":[{"given":"Iben Onsberg","family":"Hansen","sequence":"first","affiliation":[{"name":"Department of Haematology Copenhagen University Hospital Roskilde Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lindholm","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Haematology Copenhagen University Hospital Roskilde Copenhagen Denmark"},{"name":"Institute for Inflammation Research Center for Rheumatology and Spine Diseases Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"Department of Haematology Copenhagen University Hospital Roskilde Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00960.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0792"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.10"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-008805"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X385188"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659060"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.012"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.69"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009860"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394775"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.020"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.12"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.01.004"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348755"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12410"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7542"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.876356"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12437"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X316022"},{"key":"e_1_2_5_30_1","first-page":"2489","article-title":"Second malignancies in philadelphia\u2010negative myeloproliferative neoplasms\u2010single\u2010center experience","volume":"34","author":"Kissova J","year":"2014","journal-title":"Anticancer Res"},{"key":"e_1_2_5_31_1","first-page":"114","article-title":"Multiple squamous cell carcinomas of the skin during long\u2010term treatment with hydroxyurea","volume":"8","author":"Simone C","year":"1998","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2003.00534.x"},{"key":"e_1_2_5_33_1","unstructured":"HoffmanR.Randomized Trial of Pegylated Interferon Alfa\u20102a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET).http:\/\/clinicaltrialsgov\/ct2\/show\/NCT01259856. (Accessed 4 June 2015)"},{"key":"e_1_2_5_34_1","unstructured":"LarsenTS.Danish Study of Low\u2010dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph\u2010)Chronic Myeloid Neoplasms.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01387763. (Accessed 8 June 2012)"},{"key":"e_1_2_5_35_1","first-page":"30373","article-title":"Smoking as a contributing factor for development of polycythemia vera and related neoplasms","volume":"0145","author":"Hasselbalch HC","year":"2015","journal-title":"Leuk Res"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12684"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890903405753"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8540"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.175"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.3.1036"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.12.8446"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0441"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12687"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340992"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12420"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.63"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12473408860587"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442012"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23928"},{"key":"e_1_2_5_53_1","first-page":"1","article-title":"Minimal residual disease after long\u2010term interferon\u2010alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"22","author":"Utke Rank C","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.326"},{"key":"e_1_2_5_56_1","first-page":"73","article-title":"Combination therapy with interferon and JAK1\u20102 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F\u2010allele burden in polycythemia vera","volume":"3","author":"Bjorn ME","year":"2014","journal-title":"Leuk Res Rep"},{"key":"e_1_2_5_57_1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V126.23.824.824","article-title":"824 safety and efficacy of combination therapy of interferon\u2010alpha2+ JAKI\u20102 inhibitor in the Philadelphia\u2010negative chronic myeloproliferative neoplasms. Preliminary results from the Danish combi\u2010trial\u2010an open label, single arm, non\u2010randomized multicenter phase II study","volume":"126","author":"Mikkelsen SU","year":"2015","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:16:31Z","timestamp":1696292191000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,4]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/ejh.12787"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12787","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,4]]}}}